Ambrisentan
Idiopathic Pulmonary Fibrosis
Clinical trials
3
Developer
University of Pennsylvania
Overview
Ambrisentan is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 3 tracked IPF clinical trials.
Ambrisentan clinical trials
Explore related
Medical disclaimer. This page summarizes research about Ambrisentan for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.